Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 11/20 | 0.74 |
| ▸ | CACNA2D1 | P54289 | 9/20 | 0.74 |
| ▸ | CACNB1 | Q02641 | 9/20 | 0.74 |
| ▸ | CACNA1C | Q13936 | 8/20 | 0.74 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 2/20 | 0.41 |
| ▸ | MAOB | P27338 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.39 |
| ▸ | MC4R | P32245 | 1/20 | 0.39 |
| ▸ | MC1R | Q01726 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CRHBP | P24387 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2797186 | 0.89 | CACNA2D1 (0.92) | CACNA1BCACNA2D1CACNB1CACNA1CTDP1 | |
| SCHEMBL2790454 | 0.83 | CACNA2D1 (0.91) | CACNA1BCACNA2D1CACNB1CACNA1CTDP1 | |
| SCHEMBL4563663 | 0.80 | CACNA2D1 (0.81) | CACNA1BCACNA2D1CACNB1CACNA1CTDP1 | |
| SCHEMBL5017461 | 0.80 | CACNA2D1 (0.85) | CACNA1BCACNA2D1CACNB1CACNA1CTDP1 | |
| SCHEMBL2792554 | 0.79 | CACNA2D1 (0.64) | CACNA1BCACNA2D1CACNB1CACNA1CHTT | |
| SCHEMBL4279744 | 0.77 | CACNA2D1 (0.77) | CACNA1BCACNA2D1CACNB1CACNA1CMEN1 | |
| SCHEMBL3394375 | 0.75 | CACNA2D1 (0.70) | CACNA1BCACNA2D1CACNB1CACNA1CHTT | |
| SCHEMBL4279752 | 0.74 | CACNA2D1 (0.66) | CACNA1BCACNA2D1CACNB1CACNA1C | |
| SCHEMBL644607 | 0.74 | CACNA2D1 (0.60) | CACNA1BCACNA2D1CACNB1CACNA1CKMT2A | |
| SCHEMBL2791280 | 0.74 | CACNA2D1 (0.66) | CACNA1BCACNA2D1CACNB1CACNA1CKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100168103-A1 | DIARYL PIPERIDINE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2010-07-01 | — | — | US | claimed |
| EP-2061780-A1 | DIARYL PIPERIDINE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | Neuromed Pharmaceuticals, Ltd. (CA) | 2009-05-27 | — | — | EP | claimed |
| WO-2008031227-A1 | DIARYL PIPERIDINE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2008-03-20 | — | — | WO | claimed |
| US-20100168103-A1 | DIARYL PIPERIDINE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2010-07-01 | — | — | US | disclosed |
| US-20100168103-A1 | DIARYL PIPERIDINE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2010-07-01 | — | — | US | disclosed |
| US-20100168103-A1 | DIARYL PIPERIDINE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168103-A1 | DIARYL PIPERIDINE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | CACNA1C, CACNA1B, ORAI1 | CACNA1B 2/4885CACNA2D1 22/4885CACNB1 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.